12 September 2023: Original Paper
Living Donor Liver Transplantation in Patients with Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies Using Preoperative Desensitization Therapy According to Intensity of Donor-Specific Antibodies: A Single-Center Study
Kohei Ogawa ABCDEF* , Kei Tamura AB , Katsunori Sakamoto C , Naotake Funamizu B , Masahiko Honjo B , Mikiya Shine B , Yusuke Nishi B , Tomoyuki Nagaoka B , Chihiro Ito B , Miku Iwata B , Mio Uraoka B , Yasutsugu Takada ADDOI: 10.12659/AOT.941346
Ann Transplant 2023; 28:e941346
Figure 4 Changes in mean fluorescence intensity (MFI) of anti-human leucocyte antigen (HLA) antibody and the clinical course of case 3 (Microsoft, PowerPoint for Mac, ver. 16.48). (A) Anti-HLA antibodies on admission (before rituximab administration), just before liver transplantation (LT) (after plasmapheresis), on postoperative day (POD) 7, and on POD 37. (B) Clinical course of case 3. Serum bilirubin and transaminase levels increase from POD 7. Although they improved after steroid pulse therapy, they were re-elevated during steroid tapering. They were not improved after repeated steroid pulse therapy, and antithymocyte globulin (ATG) was administered. They improved gradually after ATG administration; AST – aspartate transaminase; ALT – alanine transaminase; T-Bil – total bilirubin, D-Bil – direct bilirubin.